ArticleEndocrinology and metabolism (Seoul, Korea)2020
Epidemiology and Prognosis of Pheochromocytoma/Paraganglioma in Korea: A Nationwide Study Based on the National Health Insurance Service.
Article in Endocrinology and metabolism (Seoul, Korea), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 41 citations in OpenAlex.
- An open-label, single-arm, multi-center, phase II clinical trial of single-dose [Annals of nuclear medicine · 2022Trial
- Neuroendocrine Neoplasms of the Urinary Bladder: Integrating Molecular Advances into a Refined Classification System.Endocrine pathology · 2026Review
- Laparoscopic retroperitoneal paraganglioma resection: a case description.Quantitative imaging in medicine and surgery · 2026Article
- Who can safely discontinue lifelong follow-up among patients with sporadic pheochromocytoma and paraganglioma?Journal of internal medicine · 2026Article
- Nationwide Big Data Studies of Endocrine Diseases Using the Korean National Health Information Database: Research Trends and Standardization of Operational Definitions.Endocrinology and metabolism (Seoul, Korea) · 2026Review
- Pheochromocytoma complicated with acute myocardial infarction and cerebral infarction: a case report.Frontiers in oncology · 2026Article
- A silent pheochromocytoma with regional metastasis and negative germline testing.Endocrinology, diabetes & metabolism case reports · 2026Article
- Pheochromocytoma-Induced Leukocytosis With Concurrent Severe Eosinophilia: A Case Report.Cureus · 2025Article
- Differences in Clinical Presentation Between Pheochromocytomas and Paragangliomas.Clinical endocrinology · 2025Article
- Digital Phenotyping of Rare Endocrine Diseases Across International Data Networks and the Effect of Granularity of Original Vocabulary.Yonsei medical journal · 2025Article
- Article
- Elevated Fracture Risks in Patients Using Inhaled Corticosteroids: A Korean Nationwide Study.Endocrinology and metabolism (Seoul, Korea) · 2025Article
- Analysis of the clinical characteristics of bone metastases after pheochromocytoma/paraganglioma surgery.Frontiers in endocrinology · 2025Article
- Metastatic disease and major adverse cardiovascular events preceding diagnosis are the main determinants of disease-specific survival of pheochromocytoma/paraganglioma: long-term follow-up of 303 patients.Frontiers in endocrinology · 2024Article
- Epidemiologic Profile and Clinical Outcomes of Patients with Pheochromocytoma at the University of the Philippines Philippine General Hospital (UP-PGH).Journal of the ASEAN Federation of Endocrine Societies · 2024Article
- Image-Guided Precision Medicine in the Diagnosis and Treatment of Pheochromocytomas and Paragangliomas.Cancers · 2023Review
- Big Data Research in the Field of Endocrine Diseases Using the Korean National Health Information Database.Endocrinology and metabolism (Seoul, Korea) · 2023Review
- Pheochromocytoma: a changing perspective and current concepts.Therapeutic advances in endocrinology and metabolism · 2023Review
- The Clinical Characteristics of Pheochromocytomas and Paragangliomas with Negative Catecholamines.Journal of clinical medicine · 2022Article
- Systematic Review: Incidence of Pheochromocytoma and Paraganglioma Over 70 Years.Journal of the Endocrine Society · 2022Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundPheochromocytomas and paragangliomas (PPGLs) are rare endocrine tumors originating from chromaffin cells. PPGLs are associated with a high mortality rate and several complications. To date, no epidemiological studies have been conducted on PPGLs in Asia. This study aimed to investigate the epidemiology and prognosis of PPGLs in Korea using nationwide data.
methodsUsing the National Health Insurance Service Database, subjects with a principal diagnosis of PPGLs on two or more occasions between 2003 and 2014 who satisfied the operational definition of PPGLs were included. Incidence, prevalence, complications, metastasis, and mortality were investigated.
resultsIn total, 1048 subjects with a mean age of 47.6±16.1 years were included. There was no sex preponderance. The overall prevalence of PPGLs was 2.13 per 100,000 persons, and the overall age-standardized incidence rate was 0.18 per 100,000 person-years. Malignant PPGLs accounted for 17.7% (185 of 1,048) of cases, and 94 subjects exhibited metastasis at the time of diagnosis. Among initially non-metastatic PPGLs, 9.5% (nine of 954) eventually metastasized after a mean duration of 78.1±41.4 months. The 5-year survival rates for non-metastatic and metastatic PPGLs at diagnosis were 97% and 84%, respectively. Multivariable Cox regression models adjusted for covariates showed that metastatic PPGLs were associated with a 2.40-fold higher risk of mortality than non-metastatic PPGLs (95% confidence interval, 1.38 to 4.17;
conclusionPPGLs are rare in Korea, and the prognosis of these endocrine tumors varies depending on whether they are benign or malignant. This epidemiological study paves the way for further research on PPGLs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.